About
Biography
I’m an allergist who specializes in treating children with eosinophilic gastrointestinal disorders, eosinophilic esophagitis, eosinophilia, mast cell disorders and urticaria. My research focuses on finding the most effective therapies for patients with eosinophilic and mast cell disorders.
Seeing my father work as a pediatrician inspired me to follow in his footsteps and choose medicine as a profession. I completed my formal pediatric training at Children’s Hospital of Buffalo and my allergy and immunology training at Brigham and Women’s Hospital in Boston. These experiences provided the education, skills and resources that prepared me to help my patients as a member of the Cincinnati Center for Eosinophilic Disorders (CCED).
When I care for my patients, I always put them first, with the goal of identifying their problems and working to resolve them. I strive to improve control of their symptoms. In my research, I work toward long-term control of diseases related to eosinophilic disorders and mast cell disease. I’ve published a number of journal articles in my field, and I am involved in multicenter clinical trials for eosinophilic disorders.
I was previously the interim director of the Registry for Eosinophilic Disorders. I presented the Joseph E. Ghory, MD, Memorial Lectureship for the Ohio Society of Allergy, Asthma, and Immunology; the 15th Annual Dr. John M. Karibo Memorial Lectureship; and at other national meetings related to eosinophilic and mast cell disorders. I’m also proud to be named one of Cincinnati Magazine’s Top Doctors.
Outside of the hospital, I enjoy spending time with my wife and family.
MD: University of Buffalo, Buffalo, NY, 1997.
Residency: Pediatrics, Children's Hospital of Buffalo, Buffalo, NY, 2000.
Certification: American Board of Pediatrics, 2001; American Board of Allergy and Immunology, 2003.
Interests
Immunodeficiency
Services and Specialties
Allergy and Immunology, Eosinophilic Disorders
Interests
Mast cell progenitor homing / recruitment and its involvement in allergic disorders
Research Areas
Allergy and Immunology, Eosinophilic Disorders
Additional Languages
SpanishLocations (3)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Advances and ongoing challenges in eosinophilic gastrointestinal disorders presented at the CEGIR/TIGERs Symposium at the 2024 American Academy of Allergy, Asthma & Immunology meeting. Journal of Allergy and Clinical Immunology. 2024; 154:882-892.
Losartan Treatment Reduces Esophageal Eosinophilic Inflammation in a Subset of Eosinophilic Esophagitis. The Journal of Allergy and Clinical Immunology: in Practice. 2024; 12:2427-2438.e3.
Mast cell activation syndrome: Current understanding and research needs. Journal of Allergy and Clinical Immunology. 2024; 154:255-263.
Therapeutic management of eosinophilic esophagitis. Encyclopedia of Food Allergy. : Elsevier; Elsevier; 2024.
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology. 2023; 8:803-815.
Harnessing Digital Pathology And Causal Learning To Improve Eosinophilic Esophagitis Dietary Treatment Assignment. (2023) Institute of Electrical and Electronics Engineers (IEEE). 00:1-8.
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. The Lancet Gastroenterology and Hepatology. 2023; 8:408-421.
Enhancing diversity, equity, inclusion, and accessibility in eosinophilic gastrointestinal disease research: the consortium for eosinophilic gastrointestinal disease researchers' journey. Therapeutic Advances in Rare Disease. 2023; 4:26330040231180895.
International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clinical Gastroenterology and Hepatology. 2022; 20:2474-2484.e3.
Targeted IL-4Rα blockade ameliorates refractory allergic eosinophilic inflammation in a patient with dysregulated TGF-β signaling due to ERBIN deficiency. The Journal of Allergy and Clinical Immunology: in Practice. 2022; 10:1903-1906.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey